RxDoctor Payments Data

Carolyn Coveney, MD

Family Medicine · Manlius, NYNPI 1871594234

Payments from drug & device makers

$609in general payments, 2019–2025

Across 33 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$130
  • Lilly USA, LLC$78
  • Merck$71
  • Amgen$59
  • Astellas Pharma US Inc$35
  • Intuitive Surgical$31
  • plus $206 from 11 others

What the payments were for

  • Food & beverage$609100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$609 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$90,364
Medicare patients
162
Services billed
2,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$105,009
EliquisApixaban68$49,339
TrulicityDulaglutide32$49,123
FarxigaDapagliflozin Propanediol45$39,243
JardianceEmpagliflozin25$37,664
JanuviaSitagliptin Phosphate21$30,981
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$27,948
XareltoRivaroxaban17$26,745
ProliaDenosumab12$20,627
Bydureon BciseExenatide Microspheres13$11,258
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$9,896
PaxlovidNirmatrelvir/Ritonavir12$6,610
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$6,283
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,340
Levothyroxine Sodium338$5,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$105,00990 claims
Lilly USA, LLCTrulicity$78$49,12332 claims
Boehringer IngelheimJardiance, Stiolto Respimat$21$43,00436 claims
MerckJanuvia, Lagevrio (Eua)$71$33,83834 claims
GSKTrelegy Ellipta, Incruse Ellipta$18$31,77752 claims
AmgenProlia$59$20,62712 claims
AbbVieSynthroid$130$3,62956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Manlius

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →